EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer

Xinchen Shen iD, Jiajia Zhang, Junhan Ou iD, Ziheng Bai, Tongyan Liu, Kaiyue Zhang iD, Kaixiang Zhu, James Q Wang, Chaochen Wang, Qianting Zhang, Linrong Lu, Wenwen Huang iD

Advanced Science · 2026

DOI: 10.1002/advs.202512355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Xinchen Shen und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Hydrogels, Immunomodulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple‐negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer, known for its early onset, strong metastatic tendencies, and poor prognosis. Conventional treatments, including chemotherapy and immunotherapy, often face challenges such as limited efficacy, adverse side effects, and high recurrence rates. To address these limitations, a family of tri‐block chimeric proteins, cysteine‐tagged silk‐elastin‐like proteins (cSELPs), is designed to form responsive in situ hydrogels for treating late‐stage and metastatic TNBC. These cSELPs are de novo designed to integrate multiple functional protein motifs, including a photothermal agent binding motif, silk‐inspired crosslinking motifs, and elastin‐like thermo‐responsive motifs. This unique sequence design enables the cSELP hydrogels to exhibit in situ gelation, photothermal responsive release of chemotherapeutic agent doxorubicin and immune checkpoint inhibitor anti‐PD‐L1, and antibacterial properties, leading to effective tumor microenvironment remodeling. By promoting immunogenic cell death and stimulating immune activation, this approach converts immunosuppressive “cold” tumors into immunologically active “hot” tumors. The cSELP hydrogel system demonstrates potent therapeutic efficacy against both primary and metastatic TNBC while maintaining excellent biocompatibility and long‐term safety. This protein material platform offers an innovative strategy to reshape the tumor microenvironment and combine multimodal treatments into a single biocompatible system, highlighting its potential for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsHydrogelsImmunomodulationHumansFemaleCombined Modality TherapyAnimalsMiceDoxorubicinImmunotherapyCell Line, TumorTumor MicroenvironmentGenetic EngineeringElastin

Stichwörter der Autor:innen

chimeric proteinsin situ hydrogelson‐demand drug releasestimuli‐responsive hydrogelstriple‐negative breast cancer

Substanzen

HydrogelsDoxorubicinElastin

Autor:innen und Institutionen

  • The Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • Deanery of Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh, Edinburgh, EH89AG, UK.
  • Department of Cardiology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • Department of Orthopedics of the Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310058, China.
  • State Key Laboratory of Biobased Transportation Fuel Technology, Zhejiang University, Hangzhou, 310027, China.

ORCID-Profile: Xinchen Shen, Junhan Ou, Kaiyue Zhang, Wenwen Huang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Shen, X., Zhang, J., Ou, J., Bai, Z., Liu, T., Zhang, K., Zhu, K., Wang, J. Q., Wang, C., Zhang, Q., Lu, L., & Huang, W. (2026). Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202512355

Vancouver

Shen X, Zhang J, Ou J, Bai Z, Liu T, Zhang K, et al. Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer. Advanced Science. 2026. doi:10.1002/advs.202512355

BibTeX
@article{Shen2026,
  author = {Shen, Xinchen and Zhang, Jiajia and Ou, Junhan and Bai, Ziheng and Liu, Tongyan and Zhang, Kaiyue and Zhu, Kaixiang and Wang, James Q and Wang, Chaochen and Zhang, Qianting and Lu, Linrong and Huang, Wenwen},
  title = {Genetically Engineered Light‐Responsive In Situ Hydrogels for Immunomodulation and Multimodal Therapy in Metastatic Triple‐Negative Breast Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202512355}
}
Kostenlos starten →